Celgene, BMS, Novartis expected to top 2022 orphan drug market worth $209B: report esagonowsky Fri, 03/03/2017 – 10:57 More: Celgene, BMS, Novartis expected to top 2022 orphan drug market worth 9B: report Source: fierce
read moreMylan and Biocon finally win right to sell Herceptin biosim in India even as they have taken it to U.S. and EU epalmer Fri, 03/03/2017 – 10:45 More: Mylan and Biocon finally win right to sell Herceptin biosim in India
read moreInvestors press GlaxoSmithKline to slash incoming CEO Walmsley’s pay package chelfand Fri, 03/03/2017 – 09:55 More: Investors press GlaxoSmithKline to slash incoming CEO Walmsley's pay package Source: fierce
read moreU.K. competition authority targets ‘illegal’ deals between Actavis, Concordia esagonowsky Fri, 03/03/2017 – 09:18 More: U.K. competition authority targets 'illegal' deals between Actavis, Concordia Source: fierce
read moreIntercept’s Ocaliva is being backed by the National Institute for Health and Care Excellence for routine NHS commissioning as a treatment for people with the chronic liver disease primary biliary cholangitis (PBC). Source: News
read moreAstraZeneca’s MedImmune is partnering with Sanofi’s vaccines arm Sanofi Pasteur on the development and commercialisation of its experimental monoclonal antibody MEDI8897 for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants. Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals